Floatz logo

Abatacept Recombinant

Acute Lymphoblastic Leukemia

Explore 247 assets in Acute Lymphoblastic Leukemia →
Floatz Rating
BB68/100
Confidence
Indicative
v0.2
Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07366801CT.gov
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
—Recruiting———
NCT06859424CT.gov
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
—Recruiting———
NCT06680661CT.gov
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
—Recruiting———
NCT05515029CT.gov
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
—Active Not Recruiting———
NCT01012492CT.gov
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Acute Lymphoblastic Leukemia

AssetSponsorPhaseRating
Abatacept Recombinant (this asset)Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyP3BB · 68
Gm-CsfXinhua Hospital, Shanghai Jiao Tong University School of MedicineP4BBB
Peripheral Blood Stem Cells, Allogeneic, Cd34 PositiveFred Hutchinson Cancer CenterP2/3BBB
Equine AtgInstituto Nacional de Cancer, BrazilP3BBB
Thioguanine AnhydrousSt. Jude Children's Research HospitalP4BBB
MethotrexatePrincess Maxima Center for Pediatric OncologyP4BB
Vincristine SulfateChildren's Oncology GroupP3BB
PegaspargaseDana-Farber Cancer InstituteP4BB
AsparaginaseCentre Hospitalier Universitaire de NiceP4BB

+42 more in the Acute Lymphoblastic Leukemia cohort

Other indications for Abatacept Recombinant

IndicationSponsorPhaseRating
Primary Biliary Cholangitis—P4BB · 66
Acute Biphenotypic Leukemia—P3B · 63
Acute Myeloid Leukemia—P3B · 60

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Abatacept Recombinant in Acute Lymphoblastic Leukemia. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 13, 2026.
https://terminal.floatz.ai/assets/abatacept-recombinant-acute-lymphoblastic-leukemia

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →